What is recombinant mycobacteria? how is it used cancer immunotherapy?
Best insight from top research papers
Recombinant mycobacteria are genetically modified strains used in cancer immunotherapy. These mycobacteria, such as Mycobacterium bovis, are engineered to express specific antigens or fusion polypeptides that enhance their immunotherapeutic properties. By administering pharmaceutical compositions containing these recombinant mycobacteria, particularly into the bladder, cancer treatment and prevention can be achieved. Mycobacteria, including non-pathogenic strains like Mycobacterium brumae, have shown efficacy in treating various cancers by manipulating the tumor microenvironment to stimulate immune responses against tumor cells. These modified bacteria can target tumors, colonize tumor areas, and activate immune cells through pathogen-associated molecular patterns, ultimately leading to the destruction of malignant cells.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Recombinant Mycobacteria are utilized in creating vaccines for tuberculosis, bladder cancer, autoimmune disorders, or leprosy. They induce IL-17-producing T cells, potentially aiding cancer immunotherapy. | |
20 Dec 2017 | Recombinant mycobacteria are not specifically addressed in the paper. The focus is on using viable mycobacteria like BCG or non-pathogenic mycobacteria for cancer immunotherapy in urological and renal cancers. |
| Recombinant Mycobacteria, administered via catheter, are utilized in cancer immunotherapy by delivering an expression vector to the bladder, offering a potential therapeutic approach for treating or preventing cancer. | |
| Recombinant mycobacteria are utilized in cancer immunotherapy due to their ability to stimulate anti-tumor immunity by targeting tumors and enhancing immunological recognition for malignant cell destruction. | |
11 Citations | Recombinant mycobacteria are utilized in cancer immunotherapy to manipulate the tumor microenvironment, aiding the immune system in fighting non-urological cancers by enhancing tumor clearance. |
Related Questions
What is recombinant mycobacteria? how is it made?5 answersRecombinant Mycobacteria (rMyc) are genetically modified mycobacteria that express specific proteins or fusion proteins. These modified bacteria can be used for various purposes, such as antigen production and diagnostic applications. The production of rMyc involves incorporating sequences encoding desired proteins into the mycobacterial genome, often under the control of specific promoters. For example, fusion proteins containing mycobacterial antigens can be produced abundantly by rMyc, post-translationally modified, and exhibit high antigenicity. Additionally, rMyc can mimic the diagnostic profiles of pathogens like Mycobacterium tuberculosis and Staphylococcus aureus, serving as safe and reliable quality controls for pathogen detection assays. The creation of rMyc involves advanced molecular techniques like PCR and specific antigen epitopes to enhance specificity and sensitivity in diagnostic kits.
Can Bacteria improve nanoparticles delivery to tumor?5 answersBacteria-mediated drug delivery systems have been shown to improve the delivery of nanoparticles to tumors. Anaerobic bacteria, such as Bifidobacterium, have the ability to selectively transport drug loads to the hypoxic regions of tumors. These bacteria can be used as carriers for nanoparticles, allowing for targeted drug delivery to solid tumors. By modifying the surface of bacteria with nanomaterials, hybrid bacteria systems have been developed to enhance the therapeutic efficacy of bacteria-mediated therapy. Additionally, bacteria-targeted nanoparticles have been designed to precisely target bacteria in tumors and deliver antitumor drugs, demonstrating a high tumor-targeting ability. Overall, bacteria can play a crucial role in improving the delivery of nanoparticles to tumors, offering a promising strategy for more efficient cancer treatment.
Cancer treatments with bacteria4 answersBacteria have been explored as potential cancer treatments. Researchers have made progress in using live bacteria as cancer therapeutics, although only Bacillus Calmette-Guérin is currently approved for human use. The relationship between bacteria and the emergence or development of tumors in the human body has been studied throughout history, and recent advancements have focused on forcing bacteria to serve for cancer treatment, including the creation of bacterial microrobots. Bacteria can impair the effectiveness of certain chemotherapies, and their presence can have wide-ranging effects on cancer treatment, such as affecting drug metabolism and altering toxin conversion. Bacteria-mediated antitumor therapy provides new options to address challenges in precision cancer treatment, as bacteria have the ability to destroy tumor cells and induce antitumor immune responses. The impact of bacteria on cancer is not limited to tumorigenesis, but also includes the overall susceptibility of bacteria to tumor progression and the response to anti-cancer therapy.
Can immunotherapy be used to treat cancer?4 answersImmunotherapy is a type of cancer treatment that harnesses the power of the immune system to recognize and attack cancer cells. It involves manipulating the immune response to either suppress or stimulate it, and is currently being used as a promising method for treating cancer. Efforts to use the body's own anti-tumor response have led to the discovery of alternative treatments for cancer. Immunotherapy focuses on boosting the body's own immune response against cancer tumors. A new approach to immunotherapy involves "rewiring macrophages," which could offer a fresh boost to cancer immunotherapy. Therefore, immunotherapy can be used to treat cancer by stimulating the immune system to recognize and attack cancer cells more effectively.
What is cancer immunotherspy?5 answersCancer immunotherapy is a treatment approach that utilizes the immune system to target and fight cancer cells. It involves the use of various strategies such as immune checkpoint inhibitors, adoptive cell therapy, therapeutic vaccines, and cytokines. These immunotherapies have shown promising results in the treatment of different types of cancer, including solid tumors and hematological malignancies. However, the response to immunotherapy can vary among patients, and some cancer cells develop mechanisms to resist the immune system's attack, leading to treatment resistance. Despite these challenges, immunotherapy has demonstrated improved outcomes and prolonged survival compared to traditional anti-tumor therapies. Ongoing research aims to further enhance the efficacy of immunotherapy and minimize adverse reactions by exploring new immunological checkpoints and combination therapies.
How does the microbiota affect the efficacy of cancer immunotherapy?2 answersThe microbiota plays a significant role in modulating the efficacy of cancer immunotherapy. It has been shown that the gut microbiome can influence the response to immunotherapeutic agents such as anti-PD-1 and anti-CTLA-4. The gut microorganisms can alter both antitumor and pro-tumor responses, affecting the outcomes of immunotherapy. Additionally, the gut microbiota has been found to impact the host immune response to immunotherapy, potentially enhancing its efficacy. The microbiota can also reduce the side effects of chemotherapy, further highlighting its role in cancer treatment. Understanding the mechanisms behind the microbiota-mediated modulation of the immune response is crucial for developing personalized cancer therapies. Overall, the microbiota has emerged as a key player in shaping the efficacy of cancer immunotherapy, and further research is needed to fully comprehend its impact and potential for therapeutic interventions.